EB-iAC
Low-grade cartilage lesions in joints
Pre-clinicalActive
Key Facts
About EpiBone
EpiBone is a New York-based tissue engineering company founded in 2013, developing autologous and allogenic bone and cartilage grafts. Its core technology involves extracting a patient's stem cells, seeding them onto a scaffold within a custom bioreactor that mimics the body's natural environment, and growing a personalized, living graft in 3-4 weeks. The company has advanced its lead bone graft program through a Phase I/IIa trial and has an FDA-cleared IND for a Phase I/IIb trial of its osteochondral plug, positioning it at the forefront of regenerative orthopedics. EpiBone aims to address the significant global burden of skeletal disability with biologically integrated, long-lasting solutions.
View full company profile